Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor α. Aim: In the first randomised placebo controlled trial of any drug for the treatment of PG, we have studied the role of infliximab in this disorder. Subjects: Patients 18 years of age or older with a clinical diagnosis of PG were invited to take part. Methods: Patients were randomised to receive an infusion of infliximab at 5 mg/kg or placebo at week 0. Patients were then assessed at week 2 and non-responders were offered open labelled infliximab. The primary end point was clinical improvement at week 2, with secondary end points being remission and improvement at week 6. Results: Thirty patients were entered into the study. After randomisation, 13 patients received infliximab and 17 patients received placebo. At week 2, significantly more patients in the infliximab group had improved (46% (6/13)) compared with the placebo group (6% (1/17); p = 0.025). Overall, 29 patients received infliximab with 69% (20/29) demonstrating a beneficial clinical response. Remission rate at week 6 was 21% (6/29). There was no response in 31% (9/29) of patients. Conclusions: This study has demonstrated that infliximab at a dose of 5 mg/kg is superior to placebo in the treatment of PG. Open label treatment with infliximab also produced promising results. Infliximab treatment should be considered in patients with PG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Infliximab for the treatment of fistulas in patients with Crohn's disease
Ricart, E., & Sandborn, W. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70414-2 · Cited by 519
Pyoderma Gangrenosum: A Review of 86 Patients
(1985) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a067865 · Cited by 445
Optimizing anti-TNF treatment in inflammatory bowel disease
Rutgeerts, P., van Assche, G., & Vermeire, S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.070 · Cited by 429
Bennett, M. L., Jackson, J. M., Jorizzo, J. L., Fleischer, A. B., White, W. L., & Callen, J. P. (2000) · Medicine · doi:10.1097/00005792-200001000-00004 · Cited by 404
Pyoderma gangrenosum: a report of 44 cases with follow-up
Driesch, P. V. D. (1997) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1997.20022083.x · Cited by 319
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease
Regueiro, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00430-1 · Cited by 221
Cited by
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
Van Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
Basra, M. K. A., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08832.x · Cited by 789
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Stange, E. F., Travis, S. P. L., Vermeire, S., Reinisch, W., Geboes, K., Barakauskiene, A., Feakins, R., Fléjou, J. F., Herfarth, H., Hommes, D. W., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.001 · Cited by 555
Van Assche, G., Dignass, A., Bokemeyer, B., Danese, S., Gionchetti, P., Moser, G., Beaugerie, L., Gomollón, F., Häuser, W., Herrlinger, K., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.005 · Cited by 463
Caprilli, R., Gassull, M. A., Escher, J. C., Moser, G., Munkholm, P., Forbes, A., Hommes, D. W., Lochs, H., Angelucci, E., Cocco, A., et al. (2006) · Gut · doi:10.1136/gut.2005.081950c · Cited by 428
Self-citationEtiology and Management of Pyoderma Gangrenosum: A Comprehensive Review
Ahronowitz, I., Harp, J., & Shinkai, K. (2012) · American Journal of Clinical Dermatology · doi:10.2165/11595240-000000000-00000 · Cited by 409
Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment
Alavi, A., French, L. E., Davis, M. D., Brassard, A., & Kirsner, R. S. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0251-7 · Cited by 321
ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
Gordon, H., Burisch, J., Ellul, P., Karmiris, K., Katsanos, K., Allocca, M., Bamias, G., Barreiro-de Acosta, M., Braithwaite, T., Greuter, T., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjad108 · Cited by 318
Larsen, S., Bendtzen, K., & Nielsen, O. H. (2010) · Annals of Medicine · doi:10.3109/07853890903559724 · Cited by 303
Maverakis, E., Marzano, A. V., Le, S. T., Callen, J. P., Brüggen, M.-C., Guenova, E., Dissemond, J., Shinkai, K., & Langan, S. M. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0213-x · Cited by 285
Sfikakis, P. P. (2010) · Current Directions in Autoimmunity · doi:10.1159/000289205 · Cited by 275
Diagnosis and treatment of pyoderma gangrenosum
Brooklyn, T., Dunnill, G., & Probert, C. (2006) · BMJ · doi:10.1136/bmj.333.7560.181 · Cited by 275
Self-citationOrmerod, A. D., Thomas, K. S., Craig, F. E., Mitchell, E., Greenlaw, N., Norrie, J., Mason, J. M., Walton, S., Johnston, G. A., Williams, H. C., et al. (2015) · BMJ · doi:10.1136/bmj.h2958 · Cited by 273
Clark, M., Colombel, J.-F., Feagan, B. C., Fedorak, R. N., Hanauer, S. B., Kamm, M. A., Mayer, L., Regueiro, C., Rutgeerts, P., Sandborn, W. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.006 · Cited by 224
Pyoderma gangrenosum – a guide to diagnosis and management
George, C., Deroide, F., & Rustin, M. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-3-224 · Cited by 207
Refractory ulcers: The role of tumor necrosis factor–α
Weinstein, D. A., & Kirsner, R. S. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.08.004 · Cited by 33
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review
Yamanaka, K. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17031 · Cited by 19
Metadata
- Authors
- Brooklyn, T. N., Dunnill, M. G. S., Shetty, A., Bowden, J. J., Williams, J. D. L., Griffiths, C. E. M., Forbes, A., Greenwood, R., & Probert, C. S.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-09-27
- Volume
- 55
- Issue
- 4
- Pages
- 505-509
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2125620933
- Cited by
- 646
- References
- 15
- FWCI
- 18.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.